Physician profile
Jordan Ford
NPI 1477146157
$4,117.80
in general payments reported to CMS, 2019-2025
20 companies · $404 in 2025
The $404 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $29.40 · 2022: $853 · 2023: $1,553 · 2024: $1,279 · 2025: $404.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,235.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,234.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $900.55 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $400.97 | 2022-2024 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $395.75 | 2021-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $345.33 | 2022-2025 | Fanapt, Hetlioz |
| Tris Pharma INC | $318.41 | 2022-2024 | Dyanavel Xr |
| Alkermes, INC. | $310.78 | 2022-2025 | Lybalvi, Aristada, Vivitrol |
| Lundbeck LLC | $310.46 | 2022-2025 | Rexulti |
| Bausch Health US, LLC | $230.75 | 2021-2025 | Wellbutrin, Aplenzin |
| Axsome Therapeutics, INC. | $179.87 | 2022-2024 | Auvelity |
| Noven Therapeutics, LLC | $170.66 | 2023-2024 | Xelstrym |
| Corium, LLC | $145.53 | 2023-2024 | Azstarys |
| Ironshore Pharmaceuticals INC. | $79.34 | 2022-2024 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $65.08 | 2023-2024 | Quviviq |
| Novo Nordisk INC | $53.07 | 2025 | Ozempic, Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $52.75 | 2022-2024 | Trintellix |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $40.10 | 2023-2024 | Qelbree, Qelbree |
| Tempus Ai, INC | $37.23 | 2024 | |
| Almatica Pharma LLC | $31.84 | 2023-2024 | Loreev Xr |
| Neos Therapeutics, LP | $27.49 | 2023 | Adzenys Xr-Odt |
| Sunovion Pharmaceuticals INC. | $21.84 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jordan Ford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.